EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cistracurium Besylate 10 mg/mL Solution Compounded in a Hospital Pharmacy to Prevent Drug Shortages: A Stability Study Involving Four Degradation Products

Marine Roche, Cécile Danel, Nicolas Simon iD, Mostafa Kouach, Myriam Bouchfaa, Christophe Berneron, Pascal Odou, Damien Lannoy iD

Pharmaceutics · 04.05.2023 · 15 (5) · 1404

DOI: 10.3390/pharmaceutics15051404 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 04.05.2023. Verfasst von Marine Roche und 7 weiteren Autor:innen. Beteiligte Einrichtung: ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, University Lille, F-59000 Lille, France. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Stability study of a 10 mg/mL injectable cisatracurium solution stored refrigerated in amber glass ampoules for 18 months (M18).

Methods

4000 ampoules were aseptically compounded using European Pharmacopoeia (EP)-grade cisatracurium besylate, sterile water for injection, and benzenesulfonic acid. We developed and validated a stability-indicating HPLC-UV method for cisatracurium and laudanosine. At each stability study time point, we recorded the visual aspect, cisatracurium and laudanosine levels, pH, and osmolality. Sterility, bacterial endotoxin content, and non-visible particles in solution were checked after compounding (T0) and after M12 and M18 of storage. We used HPLC-MS/MS to identify the degradation products (DPs).

Results

During the study, osmolality remained stable, pH decreased slightly, and the organoleptic properties did not change. The number of non-visible particles remained below the EP’s threshold. Sterility was preserved, and bacterial endotoxin level remained below the calculated threshold. Cisatracurium concentration remained within the ±10% acceptance interval for 15 months and then decreased to 88.7% of C0 after M18. The laudanosine generated accounted for less than a fifth of the cisatracurium degradation, and three DPs were generated—identified as EP impurity A, impurities E/F, and impurities N/O.

Conclusion

Compounded 10 mg/mL cisatracurium injectable solution is stable for at least 15 months.

Schlagwörter

Stichwörter der Autor:innen

cisatracuriumdrug compoundingdrug stabilityinjectablelaudanosine

Autor:innen und Institutionen

  • ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, University Lille, F-59000 Lille, France.
  • CHU Lille, Institut de Pharmacie, F-59000 Lille, France.

ORCID-Profile: Nicolas Simon, Damien Lannoy

Zitieren

APA

Roche, M., Danel, C., Simon, N., Kouach, M., Bouchfaa, M., Berneron, C., Odou, P., & Lannoy, D. (2023). Cistracurium Besylate 10 mg/mL Solution Compounded in a Hospital Pharmacy to Prevent Drug Shortages: A Stability Study Involving Four Degradation Products. Pharmaceutics, 15(5), 1404. https://doi.org/10.3390/pharmaceutics15051404

Vancouver

Roche M, Danel C, Simon N, Kouach M, Bouchfaa M, Berneron C, et al. Cistracurium Besylate 10 mg/mL Solution Compounded in a Hospital Pharmacy to Prevent Drug Shortages: A Stability Study Involving Four Degradation Products. Pharmaceutics. 2023;15(5):1404. doi:10.3390/pharmaceutics15051404

BibTeX
@article{Roche2023,
  author = {Roche, Marine and Danel, Cécile and Simon, Nicolas and Kouach, Mostafa and Bouchfaa, Myriam and Berneron, Christophe and Odou, Pascal and Lannoy, Damien},
  title = {Cistracurium Besylate 10 mg/mL Solution Compounded in a Hospital Pharmacy to Prevent Drug Shortages: A Stability Study Involving Four Degradation Products},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {5},
  pages = {1404},
  doi = {10.3390/pharmaceutics15051404}
}
Kostenlos starten →